Met Life Investment Management, LLC Taysha Gene Therapies, Inc. Transaction History
Met Life Investment Management, LLC
- $16.5 Billion
- Q2 2025
A detailed history of Met Life Investment Management, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 108,078 shares of TSHA stock, worth $314,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
108,078
Previous 107,711
0.34%
Holding current value
$314,506
Previous $149,000
67.11%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding TSHA
# of Institutions
138Shares Held
169MCall Options Held
70KPut Options Held
4.7K-
Avoro Capital Advisors LLC New York, NY20MShares$58.2 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$54.7 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$49 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$34.2 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY11MShares$32.1 Million1.32% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $141M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...